Celiac disease: the search for adjunctive or alternative therapies

References

• Rubio-Tapia A, Kyle RA, Kaplan EL, et al. Increased prevalence and mortality in undiagnosed celiac disease. Gastroenterol 2009;137(1):88-93
   PubMed Web of Science ®Google Scholar
• Hesham AK. 50 Years ago in the journal of pediatrics: the present state of knowledge on the celiac syndrome. J Pediatr 2010;157:214
   Web of Science ®Google Scholar
• Rubio-Tapia A, Hill ID, Kelly CP, et al. ACG clinical guidelines: diagnosis and management of celiac disease. Am J Gastroenterol 2013;108:656-76. quiz 677
   PubMed Web of Science ®Google Scholar
• Kaukinen K, Collin P, Huhtala H, Mäki M. Long-term consumption of oats in adult celiac disease patients. Nutrients 2013;5:4380-9
   PubMed Web of Science ®Google Scholar
• Pulido OM, Gillespie Z, Zarkadas M, et al. Introduction of oats in the diet of individuals with celiac disease: a systematic review. Adv Food Nutr Res 2009;57:235-85
   PubMedGoogle Scholar
• Schuppan D, Junker Y, Barisani D. Celiac disease: from pathogenesis to novel therapies. Gastroenterology 2009;137:1912-33
   PubMed Web of Science ®Google Scholar
• Van Heel DA, Franke L, Hunt KA, et al. A genome-wide association study for coeliac disease identifies risk variants in the region har- boring IL2 and IL21. Nat Genet 2007;39:827-9
   PubMed Web of Science ®Google Scholar
• Shan L, Molberg Ø, Parrot I, et al. Structural basis for gluten intol- erance in coeliac sprue. Science 2002;297:2275-9
   PubMed Web of Science ®Google Scholar
• Hu e S, Mention JJ, Monteiro RC, et al. A direct role for NKG2D / MICA interaction in villous atrophy during coeliac disease. Immunity 2004;21:367-77
   PubMed Web of Science ®Google Scholar
• Meresse B, Chen Z, Ciszewski C, et al. Coordinated induction by IL15 of a TCR-independent NKG2D signaling pathway converts CTL into lymphokine-activated killer cells in coeliac disease. Immunity 2004;21:357-66
   PubMed Web of Science ®Google Scholar
• Nilsen EM, Lundin KEA, Krajci P, et al. Gluten specific, HLA-DQ restricted T cells from coeliac mucosa produce cytokines with Th1 or Th0 profile dominated by inter-feron gamma. Gut 1995;37:766-76
   PubMed Web of Science ®Google Scholar
• Fasano A, Not T, Wang W, et al. Zonulin, a newly discovered modu- lator of intestinal permeability, and its expression in coeliac dis- ease. Lancet 2000;355:1518-19
   PubMed Web of Science ®Google Scholar
• Ehren J, Govindarajan S, Morón B, et al. Protein engineering of improved prolyl endopeptidases for celiac sprue therapy. Protein Eng Des Sel 2008;21:699-707
   PubMed Web of Science ®Google Scholar
• Hausch F, Shan L, Santiago NA, et al. Intestinal digestive resistance of immunodominant gliadin peptides. Am J Physiol Gastrointest Liver Physiol 2002;283:G996-1003
   PubMed Web of Science ®Google Scholar
• de Ritis G, Auricchio S, Jones HW, et al. In vitro (organ culture) studies of the toxicity of specific A-gliadin peptides in celiac disease. Gastroenterology 1988;94:41-9
   PubMed Web of Science ®Google Scholar
• Sturgess R, Day P, Ellis HJ, et al. Wheat peptide challenge in coeliac disease. Lancet 1994;343:758-61
   PubMed Web of Science ®Google Scholar
• Shan L, Molberg O, Parrot I, et al. Structural basis for gluten intolerance in celiac sprue. Science 2002;297:2275-9
   PubMed Web of Science ®Google Scholar
• Anderson RP, Degano P, Godkin AJ, et al. In vivo antigen challenge in celiac disease identifies a single transglutaminase-modified peptide as the dominant A-gliadin T-cell epitope. Nat Med 2000;6:337-42
   PubMed Web of Science ®Google Scholar
• Nilsen EM, Lundin KEA, Krajci P, et al. Gluten specific, HLA-DQ restricted T cells from coeliac mucosa produce cytokines with Th1 or Th0 profile dominated by inter- feron gamma. Gut 1995;37:766-76
   PubMed Web of Science ®Google Scholar
• Shan L, Molberg Ø, Parrot I, et al. Structural basis for gluten intolerance in coeliac sprue. Science 2002;297:2275-9
   PubMed Web of Science ®Google Scholar
• Siegel M, Bethune MT, Gass J, et al. Rational Design of Combination Enzyme Therapy for Celiac Sprue. Chem Biol 2006;13:649-58
   PubMed Web of Science ®Google Scholar
• Gass J, Bethune MT, Siegel M, et al. Combination enzyme therapy for gastric digestion of dietary gluten in patients with celiac sprue. Gastroenterology 2007;133:472-80
   PubMed Web of Science ®Google Scholar
• Tye-Din JA, Anderson RP, Ffrench RA, et al. The effects of ALV003 pre-digestion of gluten on immune response and symptoms in coeliac disease in vivo. Clin Immunol 2010;134:289-95
   PubMed Web of Science ®Google Scholar
• Pyle G, Paaso B, Anderson BE, et al. Low-dose gluten challenge in celiac sprue: malabsorptive and antibody responses. Clin Gastroenterol Hepatol 2005;3:679-86
   PubMed Web of Science ®Google Scholar
• Bethune MT, Strop P, Tang Y, et al. Heterologous expression, purification, refolding, and structural-functional characterization of EP-B2, a self-activating barley cysteine endoprotease. Chem Biol 2006;13:637-47
   PubMed Web of Science ®Google Scholar
• Gass J, Bethune MT, Siegel M, et al. Combination enzyme therapy for gastric digestion of dietary gluten in patients with celiac sprue. Gastroenterology 2007;133:472-80
   PubMed Web of Science ®Google Scholar
• Ehren J, Moron B, Martin E, et al. A food-grade enzyme preparation with modest gluten detoxification properties. PLoS One 2009;4:e6313
   PubMed Web of Science ®Google Scholar
• Liang L, Pinier M, Leroux JC, et al. Interaction of alpha- gliadin with polyanions: design considerations for sequestrants used in supportive treatment of coeliac disease. Biopolymers 2010;93:418-28
   PubMed Web of Science ®Google Scholar
• Lindfors K, Blomqvist T, Juuti-Uusitalo KM, et al. Live probiotic Bifidobacterium lactis bacteria inhibit the toxic effects induced by wheat gliadin in epithelial cell culture. Clin Exp Immunol 2008;152:552-8
   PubMed Web of Science ®Google Scholar
• Okada H, Kuhn C, Feillet H, et al. The ‘hygiene hypothesis’ for autoimmune and allergic diseases: an update. Clin Exp Immunol 2010;160:1-9
   PubMed Web of Science ®Google Scholar
• Mcsorley HJ, Gaze S, Daverson J, et al. Suppression of inflammatory immune responses in celiac disease by experimental hookworm infection. PLoS One 2011;6(9):e24092
   PubMed Web of Science ®Google Scholar
• Daversom AJ, Jones DM, Gaze S, et al. Effect of hookworm infection on wheat challenge in celiac disease – a randomised double-blinded placebo controlled trial. PLoS ONE 2011;6(3):e17366
   Web of Science ®Google Scholar
• de Kauwe AL, Chen Z, Anderson RP, et al. Resistance to celiac disease in humanized HLA-DR3-DQ2-transgenic mice expressing specific anti-gliadin CD4+ T cells. J Immunol 2009;182:7440-50
   PubMed Web of Science ®Google Scholar
• Brown GJ, Daveson J, Marjason JK, et al. A phase I study to determine safety, tolerability and bioactivity of Nexvax2 in HLA DQ2+ volunteers with celiac disease following a long-term, strict gluten-free diet. Gastroenterology 2011;140:S437-8
   Web of Science ®Google Scholar
• Huibregtse IL, Marietta EV, Rashtak S, et al. Induction of antigen-specific tolerance by oral administration of Lactococcus lactis delivered immunodominant DQ8-restricted gliadin peptide in sensitized nonobese diabetic Abo DQ8 transgenic mice. J Immunol 2009;183:2390-6
   PubMed Web of Science ®Google Scholar
• Utech M, Ivanov AI, Samarin SN, et al. Mechanism of IFN-gamma-induced endocytosis of tight junction proteins: myosin II-dependent vacuolarization of the apical plasma membrane. Mol Biol Cell 2005;16:5040-52
   PubMed Web of Science ®Google Scholar
• McKerracher L, Higuchi H. Targeting Rho to stimulate repair after spinal cord injury. J Neurotrauma 2006;23:309-17
   PubMed Web of Science ®Google Scholar
• LoGrasso PV, Feng Y. Rho kinase (ROCK) inhibitors and their application to inflammatory disorders. Curr Top Med Chem 2009;9:704-23
   PubMed Web of Science ®Google Scholar
• Drago S, El Asmar R, DiPierro M, et al. Gliadin, zonulin and gut permeability: effects on celiac and non-celiac intestinal mucosa and intestinal cell lines. Scand J Gastroenterol 2006;41:408-19
   PubMed Web of Science ®Google Scholar
• Fasano A, Uzzau S, Fiore C, et al. The enterotoxic effect on zonula occludens toxin on rabbit small intestine involves the paracellular pathway. Gastroenterology 1997;112:839
   PubMed Web of Science ®Google Scholar
• Marinaro M, Fasano A, DeMagistis M. Zonula occludens toxin acts as an adjuvant through different mucosal routes and induces protective immune responses. Infect Immun 2003;71:1897-902
   PubMed Web of Science ®Google Scholar
• Watts T, Berti I, Sapone A, et al. Role of the intestinal tight junction modulator zonulin in the pathogenesis of type I diabetes in BB diabetic-prone rats. Proc Natl Acad Sci USA 2005;102:2916
   PubMed Web of Science ®Google Scholar
• Paterson BM, Lammers KM, Arreta MC. The safety, tolerance, pharmacokinetic and pharmacodynamic effects of single doses of AT-1001 in coeliac disease subjects: a proof of concept study. Aliment Pharmacol Ther 2006;26:757-66
   Web of Science ®Google Scholar
• Badarau E, Collighan RJ, Griffin M. Recent advances in the development of tissue transglutaminase (TG2) inhibitors. Amino Acids 2013;44(1):119-27
   PubMed Web of Science ®Google Scholar
• Nanda N, Iismaa SE, Owens WA, et al. Targeted inactivation of Gh/tissue transglutaminase II. J Biol Chem 2001;276:20673-8
   PubMed Web of Science ®Google Scholar
• De Laurenzi V, Melino G. Gene disruption of tissue transglutaminase. Mol Cell Biol 2001;21:148-55
   PubMed Web of Science ®Google Scholar
• Marrano C, de Macedo P, Gagnon P, et al. Synthesis and evaluation of novel dipeptide-bound 1,2,4-thiadiazoles as irreversible inhibitors of guinea pig liver transglutaminase. Bioorg Med Chem 2001;9:3231-41
   PubMed Web of Science ®Google Scholar
• De Macedo P, Marrano C, Keillor JW. Synthesis of dipeptide-bound epoxides and alpha, beta-unsaturated amides as potential irreversible transglutaminase inhibitors. Bioorg Med Chem 2002;10:355-60
   PubMed Web of Science ®Google Scholar
• Choi K, Siegel M, Piper JL, et al. Chemistry and biology of dihydroisoxazole derivatives: selective inhibitors of human transglutaminase 2. Chem Biol 2005;12:469-75
   PubMed Web of Science ®Google Scholar
• Watts RE, Siegel M, Khosla C. Structure-activity relationship analysis of the selective inhibition of transglutaminase 2 by dihydroisoxazoles. J Med Chem 2006;49:7493-501
   PubMed Web of Science ®Google Scholar
• Duval E, Case A, Stein RL, et al. Structure-activity relationship study of novel tissue transglutaminase inhibitors. Bioorg Med Chem Lett 2005;15:1885-9
   PubMed Web of Science ®Google Scholar
• Pardin C, Pelletier JN, Lubell WD, et al. Cinnamoyl inhibitors of tissue transglutaminase. J Org Chem 2008;73:5766-75
   PubMed Web of Science ®Google Scholar
• Ozaki S, Ebisui E, Hamada K, et al. Potent transglutaminase inhibitors, aryl beta-aminoethyl ketones. Bioorg Med Chem Lett 2010;20:1141-4
   PubMed Web of Science ®Google Scholar
• Klöck CJ, Jin X, Choi K, et al. Acylidene oxoindoles: a new class of reversible inhibitors of human transglutaminase 2. Bioorg Med Chem Lett 2011;21(9):2692-6
   PubMed Web of Science ®Google Scholar
• Siegel M, Strnad P, Watts RE, et al. Extracellular transglutaminase 2 is catalytically inactive, but is transiently activated upon tissue injury. PLoS One 2008;3:e1861
   PubMed Web of Science ®Google Scholar
• Huang L, Haylor JL, Hau Z, et al. Transglutaminase inhibition ameliorates experimental diabetic nephropathy. Kidney Int 2009;76(4):383-94
   PubMed Web of Science ®Google Scholar
• Xia J, Bergseng E, Fleckenstein B, et al. Cyclic and dimeric gluten peptide analogues inhibiting DQ2-mediated antigen presentation in coeliac disease. Bioorg Med Chem 2007;15:6565-73
   PubMed Web of Science ®Google Scholar
• Kapoerchan VV, Wiesner M, Hillaert U, et al. Design, synthesis and evaluation of high-affinity binders for the coeliac disease associated HLA-DQ2 molecule. Mol Immunol 2010;47:1091-7
   PubMed Web of Science ®Google Scholar
• Jüse U, van de Wal Y, Koning F, et al. Design of new high-affinity peptide ligands for human leukocyte antigen-DQ2 using a positional scanning peptide library. Hum Immunol 2010;71:475-81
   PubMed Web of Science ®Google Scholar
• Gianfrani C, Levings KM, Sartirana C, et al. Gliadin-specific type 1 regulatory T cells from the intestinal mucosa of treated celiac patients inhibit pathogenic T cells. J Immunol 2006;177:4178-86
   PubMed Web of Science ®Google Scholar
• Edwards JC, Szczepanski L, Szechinski J, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004;350:2572-81
   PubMed Web of Science ®Google Scholar
• Hauser SL, Waubant E, Arnold DL, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008;358:676-88
   PubMed Web of Science ®Google Scholar
• Pescovitz MD, Bloom R, Pirsch J, et al. A randomized, double-blind, pharmacokinetic study of oral maribavir with tacrolimus in stable renal transplant recipients. Am J Transplant 2009;9:2324-30
   PubMed Web of Science ®Google Scholar
• Mei HE, Frolich D, Giesecke C, et al. Steady state generation of mucosal IgA+ plasmablasts is not abrogated by B cell depletion therapy with rituximab. Blood 2010;116:5181-90
   PubMed Web of Science ®Google Scholar
• Reinisch W, de Villiers W, Bene L, et al. Fontolizumab in moderate to severe Crohn's disease: a phase 2, randomized, double-blind, placebo-controlled, multiple-dose study. Inflamm Bowel Dis 2010;16:233-42
   PubMed Web of Science ®Google Scholar
• Yokoyama S, Watanabe N, Sato N, et al. Antibody-mediated blockade of IL-15 reverses the autoimmune intestinal damage in transgenic mice that overexpress IL-15 in enterocytes. Proc Natl Acad Sci USA 2009;106:15849-54
   PubMed Web of Science ®Google Scholar
• Herold KC, Gitelman S, Greenbaum C, et al. Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years. Clin Immunol 2009;132:166-73
   PubMed Web of Science ®Google Scholar
• Wiczling P, Rosenzweig M, Vaickus L, et al. Pharmacokinetics and pharmacodynamics of a chimeric/humanized anti-CD3 monoclonal antibody, otelixizumab (TRX4), in subjects with psoriasis and with type 1 diabetes mellitus. J Clin Pharmacol 2010;50:494-506
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Colombel JF, Frankel M, et al. Anti-CD3 antibody visilizumab is not effective in patients with intravenous corticosteroid-refractory ulcerative colitis. Gut 2010;59:1485-92
   PubMed Web of Science ®Google Scholar
• Monaco AP, Wood ML, Russell PS. Studies on heterologous antilymphocyte serum in mice. III. Immunological tolerance and chimerism produced across the H2-locus with adult thymectomy and antilymphocyte serum. Ann NY Acad Sci 1966;129:190-209
   Web of Science ®Google Scholar
• Quezada SA, Jarvinen LZ, Lind EF, et al. CD40/CD154 interactions at the interface of tolerance and immunity. Annu Rev Immunol 2004;22:307-28
   PubMed Web of Science ®Google Scholar
• Waldmann H, Cobbold S. Regulating the immune response to transplants. A role for CD4+ regulatory cells? Immunity 2001;14:399-406
   PubMed Web of Science ®Google Scholar
• Plain K M, Chen J, Merten S, et al. Induction of specific tolerance to allografts in rats by therapy with non-mitogenic, non-depleting anti-CD3 monoclonal antibody: association with TH2 cytokines not anergy. Transplantation 1999;67:605-13
   PubMed Web of Science ®Google Scholar
• Cobbold SP, Qin S, Leong LY, et al. Reprogramming the immune system for peripheral tolerance with CD4 and CD8 monoclonal antibodies. Immunol Rev 1992;129:165-201
   PubMed Web of Science ®Google Scholar
• Papadakis KA, Prehn J, Moreno ST, et al. CCR9-positive lymphocytes and thymus-expressed chemokine distinguish small bowel from colonic Crohn's disease. Gastroenterology 2001;21(2):246-54
   Google Scholar
• Rivera-Nieves J, Ho J, et al. Antibody blockade of CCL25/CCR9 ameliorates early but not late chronic murine ileitis. Gastroenterology 2006;131(5):1518-29
   PubMed Web of Science ®Google Scholar
• Keshav S, Vanásek T, Niv Y, et al. PROTECT-1 study of intestine-specific chemokine receptor antagonist CCX282-B (TRAFICET-EN) in Crohn's disease. Gut 2009;58(II):A468
   PubMed Web of Science ®Google Scholar
• Zhao J, De Vera J, Narushima S, et al. R-spondin1, a novel intestinotrophic mitogen, ameliorates experimental colitis in mice. Gastroenterology 2007;132(4):1331-43
   PubMed Web of Science ®Google Scholar
• Aziz I, Evans KE, Papageorgiou V, Sanders DS. Are patients with coeliac disease seeking alternative therapies to a gluten-free diet? J Gastrointestin Liver Dis 2011;20(1):27-31
   PubMed Web of Science ®Google Scholar
• Green PHR, Cellier C. Celiac disease. N Engl J Med 2007;357:1731-43
   PubMed Web of Science ®Google Scholar